Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
Сахарный диабет, 2014 Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ?
Alina Babenko +4 more
doaj +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Ожирение и метаболизм, 2015 Introduction: a significant improvement was shown in metabolic control at the early stages after BPD, which was associated with GLP-1 and was regardless of weight loss.Aim: to study the secretion of GLP-1, GIP, insulin and glucagon and their relationship
Ivan Ivanovich Dedov +3 more
doaj +1 more source
Incretins and bone: friend or foe? [PDF]
, 2015 To adapt to its various functions, the bone tissue is remodeled permanently and is under the influence of hormonal, local, mechanical and nervous signals.
G. Mabilleau
core +4 more sources
Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]
, 2019 Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada +2 more
core
Direct Autocrine Action of Insulin on β-Cells: Does It Make Physiological Sense? [PDF]
, 2014 In recent years there has been a growing interest in the possibility of a direct autocrine effect of insulin on the pancreatic β-cell. Indeed, there have been numerous intriguing articles and several eloquent reviews written on the subject (1–3); however,
Kahn, Steven E. +3 more
core +1 more source
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Diabetologia, 2023 C. R. Andreasen +2 more
semanticscholar +1 more source
Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons [PDF]
Endocrinology and MetabolismBackground Glucagon-like peptide-1 (GLP-1) is an incretin known for its anti-obesity effects, and several effective drugs targeting GLP-1 receptors (GLP-1Rs) have recently been developed to treat obesity.
Sujin Yoo +3 more
doaj +1 more source
Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]
, 2018 Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard +3 more
core +2 more sources
Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 2015 Introduction The hormonal brain-gut axis is a crucial element in appetite control and the response to surgical treatment for super obesity. However, mechanisms underlying the metabolic response to surgical treatment for morbid obesity are still not ...
P. Major +9 more
semanticscholar +1 more source